Details for: YERVOY
Company: BRISTOL-MYERS SQUIBB CANADA
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02379384 | YERVOY | IPILIMUMAB | 5 MG / ML | LIQUID | INTRAVENOUS |
Summary Reports
Summary Basis of Decision
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - YERVOY (ipilimumab) - Posterior Reversible Encephalopathy Syndrome (PRES)
Summary Safety Review - YERVOY (ipilimumab) - Assessing the Potential Risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Summary Safety Review - Opdivo (nivolumab) and Yervoy (ipilimumab) used alone, or in combination - Assessing the potential risk of Hemophagocytic Lymphohistiocytosis (HLH)
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - YERVOY (ipilimumab) - Posterior Reversible Encephalopathy Syndrome (PRES)
Summary Safety Review - YERVOY (ipilimumab) - Assessing the Potential Risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Summary Safety Review - Opdivo (nivolumab) and Yervoy (ipilimumab) used alone, or in combination - Assessing the potential risk of Hemophagocytic Lymphohistiocytosis (HLH)
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.